

Association between HIV co-infection and delayed diagnosis with tuberculosis bacterial load in setting with widespread antiretroviral therapy use

Juliana S. Chalfin¹, Chelsea R. Baker¹, Balladiah Kizito², Dimpho Otukile², Matsiri T. Ogopotse², Sanghyuk S. Shin^{1*}, Chawangwa Modongo^{2*}

¹Sue & Bill Gross School of Nursing, University of California Irvine, Irvine, CA, USA

²Victus Global Botswana Organisation, Gaborone, Botswana

*Co-senior author

Corresponding author:

Sanghyuk Shin, PhD

Associate Professor, Sue & Bill Gross School of Nursing

Director, UCI Infectious Disease Science Initiative

University of California Irvine

106F Berk Hall

Irvine, CA 92697

Email: sshin2@uci.edu

Phone: 949-576-8675

Word count for abstract: 242

Word count for text: 2379

Running title: HIV and TB bacterial load in Botswana

Keywords: Xpert, cycle threshold, transmission, immunosuppression, CD4 count, symptom duration

Abstract:

HIV co-infection has been shown to be associated with lower tuberculosis (TB) bacterial load in studies conducted prior to widespread availability of antiretroviral therapy (ART). The purpose of this study was to determine associations between HIV co-infection and TB bacterial load, accounting for differences in time to TB diagnosis, in a high prevalence setting with widespread ART use. In Gaborone, Botswana, 186 sputum samples from people with newly diagnosed TB were tested with Xpert MTB/RIF (Xpert). TB bacterial load and time to TB diagnosis were estimated using mean Xpert cycle threshold (CT) and symptom duration, respectively. Multiple linear regression models were used to determine the associations between HIV and Xpert CT with and without controlling for symptom duration. Mean CT values were higher in people living with HIV compared to people without HIV (21.8 vs 18.6, $p < 0.001$). Among those living with HIV, there was a negative correlation between CD4 count and mean CT value (Spearman's $\rho -0.27$, $p = 0.023$). After controlling for gender, age, and symptom duration, HIV status remained an independent predictor of CT value, with an average increase of 2.0 cycles ($p = 0.004$) among people with HIV and CD4 count > 200 cells/mm³ and 2.8 cycles ($p < 0.001$) in those with a CD4 count ≤ 200 cells/mm³ compared to individuals without HIV. Increased HIV-associated immunosuppression is associated with decreased bacterial burden even in settings with widespread ART use.

Introduction

Globally, tuberculosis (TB) has remained a leading cause of death due to an infectious disease with an estimated incidence of 10.0 million people infected and 208,000 deaths among people living with HIV (1). While the World Health Organization (WHO) has provided goals to end the global TB epidemic, recent data indicate that targets for reduced incidence rates and deaths are not being met (2). In high burden areas, HIV poses as the greatest risk factor for developing active TB, exacerbating existing susceptibility to primary infection or reactivation of latent TB (3). Southern Africa continues to report the highest prevalence of TB/HIV co-infection, demonstrating an urgent need to better understand TB transmission dynamics to reduce TB incidence and mortality (4).

The likelihood of TB transmission depends in part on the degree of infectiousness. Infectiousness can be determined by bacterial load in sputum and duration of infectiousness, which can be altered by an HIV co-infection (5). The active disease stage of TB leads to the destruction of lung tissue, generating cavities that pass *M. tuberculosis* bacteria to airways (6). Therefore, the level of lung damage contributes to the transmission potential of a TB-infected individual. However, among people with HIV and TB, lower CD4 cell counts, white blood cells that play an important role in immune function, have been associated with reduced lung inflammation (6). The reduced inflammation can result in decreased cavitation, sputum bacterial load, and ultimately reduced infectiousness, as suggested by the higher frequency of smear-negative pulmonary TB within untreated people living with HIV (6,7). Consequently, untreated HIV infection can change TB disease presentation and reduce TB infectiousness. Xpert MTB/RIF assay (Xpert) is a diagnostic test that uses real-time polymerase chain reaction (PCR). Quantitative estimation of TB bacterial load can be measured through cycle Xpert

threshold (CT) values (8). CT values convey an inverse relationship to bacterial load as a higher CT value signifies lower bacterial load and lower CT value signifies higher bacterial load. A previous study has corroborated the findings that increased immunosuppression, defined as CD4 count < 200 cells/mm³, was associated with decreased bacterial burden, measured through CT values (9).

Bacterial burden may be impacted by delays of diagnosis, as the active disease state involves bacilli replication. Delays of diagnosis may be related to barriers to healthcare access or differing severities of illness, as some patients may tolerate disease for longer before seeking treatment (5). An HIV co-infection can potentially reduce the duration of infectiousness since people with HIV are likely to be diagnosed sooner. People with HIV may have increased contact with the healthcare system as antiretroviral therapy (ART) requires regular visits, TB case finding, and prompt treatment (6). ART is the treatment of choice for managing HIV/AIDS and has significantly improved the quality of life of people living with HIV since it decreases the viral load and restores normal immune function against opportunistic pathogens (10). According to UNAIDS data from 2020, 89% of people living with HIV are on ART; yet, these prior studies were completed before ART was widely available (6,11). As ART alters the disease process of HIV, there is a gap in knowledge of whether HIV-coinfection remains associated with reduced TB infectiousness during the present time when ART is widely available.

The purpose of this study was to determine associations between HIV co-infection and TB bacterial load, including differences in duration of symptoms, in a high prevalence setting. This could contribute to understanding how HIV-coinfection affects infectiousness and transmission risk of TB in the current era of widespread ART use.

Methods

Study Design, Setting, and Population

Botswana is a country in southern Africa with a high burden of TB and among the highest rates of TB-HIV co-infection in the world. This cross-sectional analysis is part of an ongoing population-based TB transmission study in Gaborone, the capital city of Botswana. Participants were sequentially enrolled after diagnosis of TB from community or health care facilities. All participants were recruited in accordance with Botswana national guidelines. Active case finding, involving the screening of all patients, and passive case finding, involving clinical diagnosis of patients presenting with TB symptoms, were utilized in 26 public health facilities. Participants included male and female patients of all ages. Clinical and demographic data were collected through a standardized questionnaire that captured information about TB symptoms and their duration (< 1 month, 1 to 2 months, 2 to 3 months, and > 3 months prior to diagnosis). Participants provided their consent for us to access their medical records to collect TB and HIV history, including CD4 cell counts, viral load, and ART history. We recorded CT values for five probes in the Xpert test used for clinical diagnosis. Mean CT values across all probes was used as the primary measure of bacterial load.

Statistical Analysis

Standard descriptive statistics were used to characterize the data. The population median of CT values was compared between groups of HIV status and CD4 count using the nonparametric Wilcoxon test. Time to diagnosis was measured through symptom duration and dichotomized as < 1 month or \geq 1 month. Mean CT values were compared between groups of symptom duration using Wilcoxon test to determine significant difference. Spearman correlation was used to compare CD4 counts against mean CT values since values were not normally distributed. A

bivariate linear regression model was used to examine the association between mean CT value as the outcome variable and patient characteristics as predictor variables. Multivariate linear regression models were used to control for confounding variables such as age, gender, and HIV status. We compared the results of the model with and without symptom duration to estimate the extent to which the association between HIV and bacterial load is explained by differences in time to diagnosis among people with and without HIV. All statistical analyses were conducted using the R statistical software version 4.1.2 (12).

Ethics Approval

This study was approved by institutional review boards at the University of Irvine, California and Botswana Ministry of Health and Wellness Human Research Development Committee. All participants provided written consent for research use of clinical data.

Results

Sample Population

During January 2021 to February 2022, 186 participants had valid positive Xpert results with corresponding Xpert CT value results. A total of 53 individuals (22.2%) were excluded because of missing HIV result (n=31), missing symptoms duration (n=2), and missing CT values (n=20). 68.8% were male, and the median age was 34.5 (interquartile range [IQR]: 26-46) (Table 1). People with HIV comprised 38.2% with a CD4 count median of 284 cells/mm³ (IQR: 99-583). 24.2% and 43.5% reported smoking and alcohol use, respectively, at the time of enrollment. Proportion of participants reporting TB symptoms for < 1 month was 53.5% and 38.3% among people with and without HIV, respectively. Among individuals with HIV, 40.8% had \leq 200

cells/mm³, median viral load was 30.0 (IQR: 10-400), and 67.6% reported taking ART at the time of TB diagnosis (Figure 1).

Distribution of CT value

The median CT value across all participants was 19.1 (IQR: 18.0-22.8) with a range of 17.1-31.5 (Figure 1A). Mean CT values were higher among people living with HIV in comparison to people without HIV (21.8 vs 18.6, $p < 0.001$). Higher mean CT values were observed among people living with HIV with CD4 >200 cells/mm³ and ≤ 200 cells/mm³ compared to those without HIV ($p < 0.05$ for both comparisons) (Figure 2A). However, no statistically significant difference was found between the CD4 count groups among participants living with HIV (20.1 vs 23.0 for CD4 >200 cells/mm³ and ≤ 200 cells/mm³, respectively, $p = 0.25$) (Figure 2A).

Correlation of CD4 Count and CT Value

Among participants living with HIV, there was a negative correlation between CD4 count and mean CT value (Spearman's rho -0.27, $p = 0.023$; Figure 2C). In bivariate linear regression model, compared to participants without HIV, mean CT values were increased by 2.4 ($p < 0.001$) in participants living with HIV with CD4 counts >200 cells/mm³ and by an average of 3.3 ($p = <0.001$) in participants living with HIV with CD4 counts ≤ 200 cells/mm³ (Table 2).

Symptom Duration

The percentage of participants experiencing symptoms >1 month was 62% among people without HIV, 57% among those with HIV and CD4 counts > 200 cells/mm³, and 31% among those with HIV and CD4 counts ≤ 200 cells/mm³ (Figure 3). Participants living with HIV with CD4 counts ≤ 200 cells/mm³ had significantly decreased odds of symptom duration >1 month compared to those without HIV (OR 0.28, $p = 0.004$), but no statistically significant difference was found between people with HIV and CD4 count >200 cells/mm³ and people without HIV

(Table 5). Participants who reported symptoms for < 1 month had larger mean CT values compared to those that reported symptoms for one to two months prior to diagnosis (20.1 vs 18.7, $p = 0.022$) (Figure 2B). Participants that reported symptom duration < 1 month had higher mean CT values compared to those that reported symptoms for > three months prior to diagnosis (20.1 vs 18.5, $p = 0.049$) (Figure 2B). No statistical difference was found between the other four comparisons of mean CT values of symptom duration. The bivariate and multivariate linear regression models display a decreasing trend in mean CT values as the duration of symptoms increases (Table 2 and 3). However, after controlling for gender, age, and HIV status, no statistical association was found between symptom duration and mean CT (Table 3).

Individual Level Predictors of CT Value

In a multivariate linear regression model, HIV status, including the CD4 count breakdown for participants with HIV, was the only significant independent predictor of mean CT (Table 3 and Table 4). After controlling for gender, age, and symptom duration, the mean CT value was 2.0 cycles higher ($p = 0.004$) among people with HIV and CD4 count > 200 cells/mm³ and 2.8 cycles higher ($p < 0.001$) in those with a CD4 count ≤ 200 cells/mm³ compared with the reference group of individuals without HIV. In a multivariate linear regression model that only included people with HIV, no statistical association was found between CD4 count and CT when controlling for gender, age, CD4 count, viral load, and ART History (Table 4).

Discussion

Using mean CT as a measure of TB bacterial burden, we found an association between decreased bacterial burden and increased immunosuppression among people living with HIV during the time of widespread access to ART. Participants with CD4 counts ≤ 200 cells/mm³ had

the highest mean CT values on average, while people without HIV had the lowest. After controlling for gender, age, and symptom duration, this trending association continued, suggesting an independent relationship between HIV status and TB bacterial burden.

Additionally, there was a downward trend in mean CT values as the duration of symptoms increased, but when controlling for confounding variables there was no statistically significant association.

Our findings are consistent with earlier findings that those living with HIV experience lower TB bacterial burden compared to those without HIV. Xpert has been shown to be a reliable measure of bacterial burden through multiple studies (9,13). Additionally, a retrospective study compared CT values collected from sputum and saliva from both people living with and without HIV (14). Burger et al. concluded that patients living with HIV had significantly lower bacterial load than individuals without HIV, and sputum is the optimal sample type for Xpert analysis (14). Combined, these studies support the observation that HIV changes the presentation of TB, with less inflammation and cavitation leading to lower TB bacterial load (9,13).

As ART decreases the viral load and restores normal immune function, it has the potential to shift towards a TB disease presentation to be similar to those without HIV. A study using smear microscopy found that ART increased smear positivity and cavitation among participants with HIV, with lower proportions compared to individuals without HIV (15). As ART has a positive relationship with CD4 count, we expected higher CD4 counts among people with HIV in our study and similar levels of TB bacterial load by HIV status. However, our data show a proportion of people with HIV/TB co-infection have advanced immune suppression and, therefore, TB bacterial load remains lower among people living with HIV compared to those without HIV even in settings with widespread ART use.

Symptom duration prior to diagnosis can be used as a measure of diagnostic delay. Our data suggests a negative correlation between symptom duration and bacterial load but found no statistical association after controlling for other variables. Previous studies suggest that people living with HIV are more likely to be diagnosed faster due to more severe symptoms or increased contact with healthcare systems (6). Our data supports this finding since a significant difference was found between HIV status and symptom duration for < one month before diagnosis; however, there was no statistical significance found in the multivariate model for symptom duration in predicting CT values. Our findings suggest that the association between HIV associated immunosuppression and CT values is due to differences in pathophysiology and not due to differences in timeliness of TB diagnosis between people with and without HIV.

While the cross-sectional design allows us to study multiple variables, it results in limitations for the application of our findings. HIV status was found to be an independent predictor of bacterial burden, and infectiousness; yet, a causal relationship cannot be established. Predictors of CT values are important to understand since the level of bacterial load affects transmission. Future studies should continue to examine HIV status in relation to TB transmission among close contacts to directly demonstrate the applicability of CT values in determining transmission risks.

In conclusion, our data demonstrate that HIV status remains an independent predictor of TB infectiousness while ART is widely available, since increased immunosuppression is associated with decreased bacterial burden, measured through Xpert CT values. Duration of symptoms was not found to be associated with TB infectiousness, regardless of HIV status. As resources are limited and TB contact tracing is foundational for disease control and prevention, these findings suggest prioritizing individuals living without HIV or have low CT values since

they may be more likely to transmit TB. Further research should directly assess TB outcomes and transmission based on CT results in order to advance understanding of its utility in clinical and community health practice.

References:

1. Global Tuberculosis Report 2021 [Internet]. [cited 2022 Mar 27]. Available from: <https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021>
2. Tuberculosis (TB) [Internet]. [cited 2022 Mar 27]. Available from: <https://www.who.int/news-room/fact-sheets/detail/tuberculosis>
3. Bruchfeld J, Correia-Neves M, Källenius G. Tuberculosis and HIV Coinfection. *Cold Spring Harb Perspect Med*. 2015 Jul 1;5(7):a017871.
4. Akwafuo SE, Akwafuo SE. Evaluation of the Burden and Intervention Strategies of TB-HIV Co-Infection in West Africa. [cited 2022 Mar 27]; Available from: <https://www.clinmedjournals.org/articles/jide/journal-of-infectious-diseases-and-epidemiology-jide-6-143.php?jid=jide>
5. Dye C, Williams BG. The Population Dynamics and Control of Tuberculosis. *Science*. 2010 May 14;328(5980):856–61.
6. Peters JS, Andrews JR, Hatherill M, Hermans S, Martinez L, Schurr E, et al. Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings. *Lancet Infect Dis*. 2019 Mar 1;19(3):e65–76.
7. Kwan CK, Ernst JD. HIV and Tuberculosis: a Deadly Human Syndemic. *Clin Microbiol Rev*. 2011 Apr;24(2):351–76.
8. Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. *Future Microbiol*. 2011 Sep;6(9):1067–82.
9. Hanrahan CF, Theron G, Bassett J, Dheda K, Scott L, Stevens W, et al. Xpert MTB/RIF as a Measure of Sputum Bacillary Burden. Variation by HIV Status and Immunosuppression. *Am J Respir Crit Care Med*. 2014 Jun;189(11):1426–34.
10. Treatment | Living with HIV | HIV Basics | HIV/AIDS | CDC [Internet]. 2021 [cited 2022 Mar 27]. Available from: <https://www.cdc.gov/hiv/basics/livingwithhiv/treatment.html>
11. UNAIDS data 2020 [Internet]. [cited 2022 Mar 27]. Available from: <https://www.unaids.org/en/resources/documents/2020/unaid-data>
12. R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, 2018).
13. Beynon F, Theron G, Respeito D, Mambuque E, Saavedra B, Bulu H, et al. Correlation of Xpert MTB/RIF with measures to assess Mycobacterium tuberculosis bacillary burden in high HIV burden areas of Southern Africa. *Sci Rep*. 2018 Mar 26;8(1):5201.
14. Burger ZC, Aung ST, Aung HT, Rodwell T, Seifert M. 658. Effect of HIV Status on Tuberculosis Load as Detected by Xpert MTB/RIF in Sputum vs. Saliva Samples. *Open Forum Infect Dis*. 2020 Oct 1;7(Supplement_1):S385–6.
15. Munthali L, Khan PY, Mwaungulu NJ, Chilongo F, Floyd S, Kayange M, et al. The effect of HIV and antiretroviral therapy on characteristics of pulmonary tuberculosis in northern Malawi: a cross-sectional study. *BMC Infect Dis*. 2014 Feb 25;14(1):107.

Images and Figures

Table 1: Demographic and Clinical Information by HIV Status of Individuals in Botswana 2021-2022

	Negative (N=115)	Positive (N=71)	Overall (N=186)
Gender			
Female	35 (30.4%)	23 (32.4%)	58 (31.2%)
Male	80 (69.6%)	48 (67.6%)	128 (68.8%)
Age			
0-19	14 (12.2%)	0 (0%)	14 (7.5%)
20-29	44 (38.3%)	10 (14.1%)	54 (29.0%)
30-39	26 (22.6%)	23 (32.4%)	49 (26.3%)
40-49	14 (12.2%)	19 (26.8%)	33 (17.7%)
50-65	11 (9.6%)	19 (26.8%)	30 (16.1%)
65+	6 (5.2%)	0 (0%)	6 (3.2%)
Currently Smoking			
Yes	29 (25.2%)	16 (22.5%)	45 (24.2%)
No	86 (74.8%)	55 (77.5%)	141 (75.8%)
Currently Drinking Alcohol			
Yes	51 (44.3%)	30 (42.3%)	81 (43.5%)
No	64 (55.7%)	41 (57.7%)	105 (56.5%)
Symptom Duration			
<1 month	44 (38.3%)	38 (53.5%)	82 (44.1%)
1-2 months	46 (40.0%)	24 (33.8%)	70 (37.6%)
2-3 months	12 (10.4%)	7 (9.9%)	19 (10.2%)
3+ months	13 (11.3%)	2 (2.8%)	15 (8.1%)
HIV Status			
HIV-	115 (100%)	0 (0%)	115 (61.8%)
HIV+ CD4 > 200	0 (0%)	42 (59.2%)	42 (22.6%)
HIV+ CD4 ≤ 200	0 (0%)	29 (40.8%)	29 (15.6%)

Figure 1: (A) Histogram of individuals' mean CT values among all participants. (B) Histogram of individuals' CD4 counts among participants living with HIV. (C) Histogram of individuals' viral load among participants living with HIV. (D) Bar graph of frequency, measured in percent, of ART history among participants living with HIV.




Figure 2: (A) Boxplot comparing mean CT values between HIV status and CD4 count, among those living with HIV. (B) Boxplot comparing mean CT values between groups of symptoms duration prior to diagnosis, measured in months.




Table 2: Bivariate Linear Regression Model for Mean CT Value among All Participants

Characteristic	N	Beta	95% CI [†]	p-value
Gender	186			
Female		—	—	
Male		-0.48	-1.7, 0.77	0.45
Age	186	0.05	0.01, 0.09	0.013
Currently Smoking	186			
Yes		—	—	
No		0.72	-0.64, 2.1	0.30
Currently Drinking Alcohol	186			
Yes		—	—	
No		0.58	-0.59, 1.7	0.33
Symptom Duration	186			
<1 month		—	—	
1-2 months		-1.4	-2.6, -0.12	0.032
2-3 months		-2.0	-3.9, 0.03	0.053
3+ months		-2.4	-4.6, -0.19	0.033
HIV Status	186			
HIV-		—	—	
HIV+ CD4 > 200		2.4	1.1, 3.7	<0.001
HIV+ CD4 ≤ 200		3.3	1.8, 4.9	<0.001
CD4 Count	71	0.00	-0.01, 0.00	0.036
Viral Load	59	0.00	0.00, 0.00	0.84
ART History	71			
Patient has never taken ARTs		—	—	
Patient is taking ARTs		-1.9	-4.5, 0.72	0.15
Patient took ARTs but stopped		-3.5	-7.4, 0.43	0.081

[†] CI = Confidence Interval

Table 3: Multivariate Regression Models for Mean CT among All Participants

Characteristic	Beta	95% CI [†]	p-value	Characteristic	Beta	95% CI [†]	p-value
Gender				Gender			
Female	—	—		Female	—	—	
Male	-0.68	-1.9, 0.53	0.3	Male	-0.72	-1.9, 0.49	0.2
Age	0.03	-0.01, 0.07	0.15	Age	0.03	-0.01, 0.07	0.2
HIV Status				HIV Status			
HIV-	—	—		HIV-	—	—	
HIV+ CD4 > 200	2.1	0.73, 3.5	0.003	HIV+ CD4 > 200	2.0	0.64, 3.4	0.004
HIV+ CD4 ≤ 200	3.1	1.5, 4.7	<0.001	HIV+ CD4 ≤ 200	2.8	1.1, 4.4	<0.001
† CI = Confidence Interval				Symptom Duration			
				<1 month	—	—	
				1-2 months	-1.0	-2.3, 0.20	0.10
				2-3 months	-1.6	-3.5, 0.25	0.089
				3+ months	-1.5	-3.6, 0.65	0.2
				† CI = Confidence Interval			

Table 4: Multivariate Regression Model for Mean CT among Participants Living with HIV

Characteristic	Beta	95% CI [†]	p-value
Gender			
Female	—	—	
Male	-0.54	-3.2, 2.1	0.7
Age	-0.03	-0.15, 0.09	0.7
CD4 Count by 10	-0.04	-0.09, 0.01	0.092
Log10 Viral Load	-0.57	-2.2, 1.1	0.5
ART History			
Patient has never taken ARTs	—	—	
Patient is taking ARTs	-0.20	-4.1, 3.7	>0.9
Patient took ARTs but stopped	-1.5	-6.2, 3.2	0.5
† CI = Confidence Interval			

Figure 3: Comparison of Symptom Duration >1 Month by HIV Status and CD4 Count Breakdown




Table 5: Odds Ratio for Symptom Duration >1 Month by HIV Status and CD4 Count Breakdown

Characteristic	OR [†]	95% CI [†]	p-value
HIV status			
HIV-	—	—	
HIV+ CD4 > 200	0.83	0.40, 1.71	0.6
HIV+ CD4 <= 200	0.28	0.11, 0.65	0.004

[†]OR = Odds Ratio, CI = Confidence Interval